Panitumumab. en las nuevas guías de CCRm - page 35

GRUPO 1: In RAS WT tumors, anti-EGFR may be more effective

than bevacizumab in terms of tumor shrinkage (II, B).

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,25,26,27,28,29,30,31,32,33,34 36,37,38,39,40,41,42,43,44,45,...47